- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05868226
Programme PRE-I-SPY Phase I/Ib (PRE-ISPY)
PRE-investigation d'études en série pour prédire votre réponse thérapeutique avec l'imagerie et l'analyse moléculaire : un essai de plate-forme de phase I/Ib
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/or a high risk of recurrence following prior treatment with curative intent. The overall goal is moving promising drug regimens into a larger phase II (or III) trial and in general could feed the neoadjuvant breast I-SPY 2 Trial (NCT01042379) and/or other oncology solid tumor trial in a timely manner.
Aperçu de l'étude
Statut
Les conditions
- Adénocarcinome
- Tumeurs colorectales
- Cancer rectal
- Tumeurs rectales
- Tumeur solide
- Cancer métastatique
- Cancer du sein métastatique
- Cancer du sein triple négatif
- Cancer du sein HER2 positif
- Cancer du colon
- Tumeurs du côlon
- Cancer colorectal
- Tumeur résiduelle
- Maladie résiduelle minimale
- Tumeur solide, adulte
- Carcinome solide
- Cancer du sein métastatique HER2 positif
- Cancer du sein positif aux récepteurs de la progestérone
- Cancer du sein HER2 négatif
- Tumeur positive aux récepteurs des œstrogènes
- Cancer du sein à récepteurs hormonaux positifs
- Métastatique
- Surexpression de la protéine HER-2
- Cancer du sein PR-positif
- Carcinome du sein à récepteurs hormonaux négatifs
- Cancer du sein bas HER2
- Tumeurs liées à la mutation HER2
- RH positif
- Cancer du sein ER positif
- Surveillance de l'ADNct
- Adénocarcinome du côlon
- Carcinome bas du sein HER2
Description détaillée
The PRE-ISPY/I-SPY-P1 study is a platform trial with multiple ongoing drug regimen arms. Each drug regimen arm may have a Phase I dose-finding group (Part 1), a dose-expansion group (Part 2), and/or a Phase II component. Participant eligibility may vary according to the investigational arm or the part within the study arm, including with respect to diagnosis. Arms may restrict enrollment to a certain molecular pathway abnormality or histologic diagnosis (e.g. metastatic TNBC or MRD CRC). The trial allows for various study arm designs, with the goal to complete analysis of a study arm in 12 to 18 months.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Smita M Asare
- Numéro de téléphone: 104 (855) 866-0505
- E-mail: smita.asare@qlhc.org
Sauvegarde des contacts de l'étude
- Nom: Maria Pitsiouni, PhD
- Numéro de téléphone: 172 (415) 651-8047
- E-mail: m.pitsiouni@qlhc.org
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Recrutement
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
-
Chercheur principal:
- Erica Stringer-Reasor, MD
-
Contact:
- Anethea Tolliver
- Numéro de téléphone: 205-644-9896
- E-mail: anetheatolliver@uabmc.edu
-
Contact:
- Lindsey M Waldheim
- E-mail: lwaldheim@uabmc.edu
-
Sous-enquêteur:
- Nusrat Jahan, MD
-
Sous-enquêteur:
- Gabrielle Rocque, MD
-
Sous-enquêteur:
- Midhun Malla, MD
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85054
- Pas encore de recrutement
- Mayo Clinic Comprehensive Cancer Center
-
Sous-enquêteur:
- Mojun Zhu, MD
-
Contact:
- Clinical Trials Referral Office
- Numéro de téléphone: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Sous-enquêteur:
- Lida Mina, MD
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Actif, ne recrute pas
- University of Colorado Cancer Center
-
-
Florida
-
Tampa, Florida, États-Unis, 33612
- Actif, ne recrute pas
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- The University of Chicago Medicine Comprehensive Cancer Center
-
Chercheur principal:
- Nan Chen, MD
-
Sous-enquêteur:
- Rita Nanda, MD
-
Contact:
- Clara Duarte
- Numéro de téléphone: 773-834-5727
- E-mail: vqq5698@bsd.uchicago.edu
-
Sous-enquêteur:
- Ardaman Shergill, MD, MSPH
-
New Lenox, Illinois, États-Unis, 60451
- Recrutement
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital
-
Chercheur principal:
- Nan Chen, MD
-
Contact:
- Clara Duarte
- Numéro de téléphone: 773-834-5727
- E-mail: vqq5698@bsd.uchicago.edu
-
Orland Park, Illinois, États-Unis, 60462
- Recrutement
- UChicago Medicine Orland Park
-
Chercheur principal:
- Nan Chen, MD
-
Contact:
- Clara Duarte
- Numéro de téléphone: 773-834-5727
- E-mail: vqq5698@bsd.uchicago.edu
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- Recrutement
- University of Minnesota Masonic Cancer Center
-
Chercheur principal:
- David Potter, MD, PhD
-
Contact:
- Katie Vaughn, RN
- Numéro de téléphone: 612-624-6968
- E-mail: schro811@umn.edu
-
Contact:
- Erin Rogers
- E-mail: roge0507@umn.edu
-
Sous-enquêteur:
- Anne Blaes, MD, MS
-
Sous-enquêteur:
- Emil Lou, MD, PhD
-
Rochester, Minnesota, États-Unis, 55905
- Pas encore de recrutement
- Mayo Clinic Comprehensive Cancer Center
-
Sous-enquêteur:
- Zhaohui Jin, MD
-
Contact:
- Clinical Trials Referral Office
- Numéro de téléphone: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Chercheur principal:
- Roberto A Leon-Ferre, MD
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Actif, ne recrute pas
- The University of Texas MD Anderson Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
General Inclusion Criteria (GIC):
-
GIC1: The participant must have ability to understand and willingness to provide signed written informed consent prior to any study related assessments and procedures and for collection of archival FFPE blocks for research. If FFPE blocks cannot be submitted, 20 to 40 freshly cut FFPE tissue slices (4 to 7 microns thick each) from a representative FFPE block, mounted on charged glass slides and left unstained will be acceptable. This criteria can be modified in specific drug regimens.
-
GIC2: Age ≥ 18 years at the time of signing the informed consent
-
GIC3: Gender: Male or female (premenopausal and postmenopausal)
-
GIC4: ECOG performance status Grade 0-2. This criteria can be modified in specific drug regimens.
-
GIC5: Estimated life expectancy > 12 weeks at the start of investigational medicinal product (IMP) treatment.
-
GIC6: Adequate organ function, evidenced by the following laboratory results within 30 days of the start of IMP:
- Absolute neutrophil count ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- Hemoglobin ≥ 9.0 g/dL with no blood transfusion in the past 28 days
- Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN
- Estimated Creatinine clearance (using Cockcroft-Gault formula) ≥ 60 mL/min for small molecules and >30 mL/min for monoclonal antibodies unless otherwise specified in the Arm Specific Eligibility.
These cut-off values may be modified with supporting data for specific drug regimens.
- GIC7: Non-Pregnant: Serum or urine pregnancy test must be negative within 14 days of IMP treatment start in women of childbearing potential. Pregnancy testing does not need to be pursued in patients who are judged as postmenopausal before enrollment, or who have undergone bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation. If male, they must agree to refrain from donating sperm during treatment.
- GIC8: Contraception: Women of childbearing potential and men must be willing to use adequate contraception for the duration of protocol treatment. Additional information regarding contraception for the specific treatment arm will be added to the drug arm description. Adequate contraception is defined as one highly effective form (i.e., abstinence, (fe)male sterilization) OR two effective forms (e.g., non-hormonal IUD and condom / occlusive cap with spermicidal foam / gel / film / cream / suppository).
- GIC9: Prior therapy effects: Resolution of all acute toxic effects of prior therapy, including radiotherapy, to grade ≤1 and neuropathy to grade ≤2 (except toxicities not considered a safety risk for the patient) and recovery from surgical procedures.
- GIC10: Participant compliance: Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Additional arm specific inclusion criteria as needed by drug arm regimen
General Exclusion Criteria (GEC):
-
GEC1: Wash out periods: Other anticancer therapy within the following period:
- chemotherapy or investigational agents, 3 weeks
- mitomycin C and nitrosoureas, 6 weeks
- if radiotherapy is less than 5 days, 1 week wash out; if >5 days, then 2 weeks washout
- for radionuclides, contact Study PI or Study Chaperone to determine washout
- targeted therapy, 2 weeks
- MAbs, ADCs, and immunotherapy, 3 weeks
- endocrine therapy, no washout needed
-
GEC2: Concurrent therapy with other Investigational Products.
-
GEC3: Prior history of drug/regimen hypersensitivity: History of infusion-related reactions and/or hypersensitivity to IMP or excipients of the study drug/drugs which led to permanent discontinuation of the treatment.
-
GEC4: Uncontrolled intercurrent illness including active infection, diabetes, adrenal insufficiency, pulmonary embolism, stroke in the past 6 months, or psychiatric illness/social situations that would limit compliance with study requirements.
-
GEC5: Cardiovascular disease: History (within 6 months prior to start IMP) of clinically significant cardiovascular disease such as unstable angina, congestive heart failure (CHF), myocardial infarction, uncontrolled hypertension, cardiac arrhythmia requiring medication, or baseline corrected QT by Fridericia's formula (QTcF) length > 470 msec for men and women. The QTcF cut-off value may be modified with supporting data for specific drug regimens.
-
GEC6: CNS tumoral spread: Active uncontrolled/symptomatic central nervous system cancer/spinal cord compression. Previously treated and clinically stable lesions, as per Investigator's judgment, are permitted. Exception: Newly discovered asymptomatic lesions that are not life threatening and do not require urgent local treatment to ensure patient safety, including new parenchymal lesions or leptomeningeal disease, if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy, after consultation with study regimen chaperones, may be permitted. This criteria can be modified in specific drug regimens.
-
GEC7: Liver disease: Patients with clinically significant history of liver disease, including viral or other known hepatitis, current alcohol abuse, or cirrhosis.
-
GEC8: Recent major surgery within 4 weeks prior to start IMP treatment
-
GEC9: Pregnancy or breastfeeding
-
GEC10: Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized.
-
GEC11: Other conditions, which in the opinion of the investigator, would compromise the safety of the patient or the patient's ability to complete the study.
-
GEC12: Concomitant malignancies: A diagnosis of a malignancy in the 2 years prior to starting study treatment other than the disease under study. Exceptions include indolent or definitively treated malignancy not expected to require treatment during the study, affect the safety of participants, or affect the endpoints of the trial.
-
Additional arm specific exclusion criteria as needed by drug arm regimen
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: PRE1 ALX148 (Evorpacept) + Fam-Trastuzumab Deruxtecan-Nxki (T-DXd, Enhertu®)
The combination of T-DXd and ALX148 aims to explore the anti-tumoral effects of trastuzumab, of the topoisomerase inhibitor DXd and of the CD47-blocking agent ALX148. The rationale for this combination is that ALX148 is hypothesized, based on preclinical data, to facilitate antibody-dependent cellular phagocytosis (ADCP) of HER2 expressing (>HER2 1+) breast cancer binding T-DXd while cancer cell intrinsic or bystander cytotoxicity of T-DXd will result in the release of neoantigens promoting immune mediated antitumor activity in the tumor microenvironment. |
Starting dose Dose Level 1 30mg/kg IV Q3W; Dose Level Minus 1 20 mg/kg IV Q3W (if needed); Dose Level 2 45 mg/kg IV Q3W;
Autres noms:
5.4 mg/kg IV Q3W; allowed to dose reduce after DLT observation period
Autres noms:
|
|
Expérimental: PRE2 Zanidatamab (Ziihera®, ZW25, zani) + Tucatinib (TUKYSA®)
Zanidatamab is a bispecific IgG1-like antibody directed against two distinct HER2 epitopes. It induces formation of receptor clusters and internalization resulting in downregulation. It also inhibits growth factor-dependent and -independent tumor cell proliferation and potently activates ADCC, ADCP, and CDC. FDA approved for metastatic HER2+ bile duct cancer. Tucatinib is a highly selective, small molecule tyrosine kinase inhibitor (TKI) of HER2 compared to other TKI's (i.e., EGFR). It is well tolerated, crosses the blood brain barrier and can treat CNS disease. FDA approved for HER2+ breast cancer. Given the promising clinical data for each of these drugs which have different mechanisms, the effect of zanidatamab after T-DXd (Enhertu®) in breast cancer patients, and the favorable toxicity profile of both drugs, we hypothesize that the combination of tucatinib and zanidatamab will be well tolerated and more efficacious than either drug alone for the treatment of HER2+ breast cancer. |
20 mg/kg IV Q2W on Day 1 and Day 15 of each 28 day cycle
Autres noms:
Dose Level 1: 300 mg PO BID daily; Dose Leve Minus 1: 250 mg PO BID daily
Autres noms:
|
|
Expérimental: PRE4 TTX-MC138
TTX-MC138 is an antisense oligonucleotide targeting miR-10b. MicroRNA-10b (miR-10b) was identified in metastatic cell lines and tumors from participants with metastatic breast cancer and has been shown to regulate the ability of metastatic tumor cells to survive outside of the primary tumor and to migrate and invade surrounding tissue. miRNA-10b is critical to tumor growth and is a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblast. This is a PRE-ISPY PHASE II study of TTX-MC138 as interception treatment in patients with Stage I-III adenocarcinoma of the colon or rectum (Cohort A) who have documented minimal residual disease by tumor informed ctDNA, that was collected following completion of standard therapy with curative intent. |
4.8 mg/kg Q4W IV on Day 1 for up to 12 cycles as interception therapy |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Adverse Events related to the treatment
Délai: Start of treatment to 30 days post treatment (estimated 12 -18 months)
|
Evaluate the number of adverse events related to the treatment according to the current version of CTCAE during the trial. |
Start of treatment to 30 days post treatment (estimated 12 -18 months)
|
|
For Phase Ib Part 1 study design: Incidence of Dose Limiting Toxicities (DLTs) at each dose level
Délai: DLT observation period: Start of treatment to end of Cycle 1
|
To determine the safety and tolerability of new agents/regimens in participants with certain advanced solid tumors and breast cancer. DLT rate (number of participants who experience a protocol defined DLT/total number of DLT cohort participants at that dose). |
DLT observation period: Start of treatment to end of Cycle 1
|
|
For select drug arms, Maximum Tolerated Dose (MTD)
Délai: Start of treatment to the date of last participant at end of DLT observation period at highest dose level (estimated 6 months)
|
The maximum dose level (mg/kg) which is not eliminated. |
Start of treatment to the date of last participant at end of DLT observation period at highest dose level (estimated 6 months)
|
|
For Phase Ib Part 1 drug arms, Recommended Phase 2 Dose (RP2D)
Délai: Start of treatment to the date of last participant at highest dose level (estimated 6 months)
|
Using all available data, computation of RP2D (mg/kg), which may not be the MTD. |
Start of treatment to the date of last participant at highest dose level (estimated 6 months)
|
|
Overall Response Rate (ORR)
Délai: Start of treatment to 12 months
|
To obtain preliminary efficacy data of the new agents/regimens in participants with certain advanced solid tumors and breast cancer. |
Start of treatment to 12 months
|
|
Duration of Response (DOR)
Délai: Start of treatment to 12 months
|
To obtain preliminary efficacy data of the new agents/regimens in participants with certain advanced solid tumors and breast cancer. |
Start of treatment to 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression Free Survival (PFS) - descriptive
Délai: Start of treatment to 12 months
|
To provide descriptive assessment of Progression Free Survival (PFS) of the new agents/regimens with certain advanced solid tumors and breast cancer |
Start of treatment to 12 months
|
|
Clinical Benefit Rate (CBR) at 6 months
Délai: Start of treatment to 6 months
|
To obtain preliminary Clinical Benefit Rate (CBR) at 6 months of participants treated with the new agents/regimens. |
Start of treatment to 6 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Paula R Pohlmann, MD, MSc, PhD, M.D. Anderson Cancer Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- La phase I
- Phase II
- Phase 2
- ARN
- ALX148
- Evorpacept
- T-DXd
- Essais I-SPY
- Collaboration Quantum Leap Healthcare
- QLHC
- Tucatinib
- Enhertu
- micro-ARN
- QL
- Tukysa
- J'ESPIONNE
- I-SPY2
- I-SPY1
- PRÉ-ISPY
- PRE-I-SPY
- I-SPY Phase 1
- I-SPY Phase 1b
- I-SPY-P1
- J'ESPIONNE
- ISPYP1
- Plateforme I-SPY Phase 1
- ISPY2
- ISPY1
- Plate-forme Phase 1
- Plateforme Oncologie Phase 1
- T-DXd naïf
- PRE1
- PRÉ2
- PRÉ3
- Zanidatamab
- PRÉ
- Phase pré-i-i-py
- Phase pré-i-i-py
- Ziihera
- K-SPY
- KSPY
- QuantumLeap
- PRE-ISPY NCT
- PRE-ISPY Network
- PRE-ISPY Phase 2
- PRE-ISPY Phase 1
- PRE-ISPY Phase I
- miRNA-10b
- PRE-I-SPY Phase 2
- PRE-I-SPY Phase II
- preispy
- PRE4
- PRE5
- PRE6
- TTX-MC138
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs par site
- Tumeurs
- Maladies intestinales
- Tumeurs par type histologique
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs intestinales
- Maladies rectales
- Tumeurs, glandulaires et épithéliales
- Maladies du côlon
- Processus néoplasiques
- Maladies de la peau
- Maladies du sein
- Carcinome
- Conditions pathologiques, signes et symptômes
- Maladies de la peau et du tissu conjonctif
- Tumeurs rectales
- Tumeurs colorectales
- Tumeur résiduelle
- Tumeurs du côlon
- Tumeurs mammaires
- Métastase néoplasmique
- Adénocarcinome
- Tumeurs mammaires triples négatives
- tucatinib
- zanidatamab
- Alx148
Autres numéros d'identification d'étude
- I-SPY-P1
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .